Noticias y Actividades de Oculis
Ejecutivos
Ver el organigrama con sus 16 ejecutivos principales
Biografías más buscadas en Oculis
- Riad Sherif, Chief Executive Officer and Director
- Geraldine O'Keeffe, Director
- Anthony Rosenberg, Chairman of the Board
Recientes movimientos de ejecutivos en Oculis
- Daniel Char, se ha incorporado a la empresa como Chief Legal Officer (noticia publicada el 2 de octubre de 2024).
- Sharon Klier, se ha incorporado a la empresa como Chief Development Officer (noticia publicada el 18 de agosto de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en Oculis.
Farmacia
Oculis tiene 1.833 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).
Popular M&A news in Farmacia
- Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
- Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publicado el 12 de marzo de 2025).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Oculis
- Oculis Reports Q3 2023 Financial Results and Provides Company Update | Oculis
- News Releases | Oculis
- Oculis to Present at Upcoming November Investor Conferences | Oculis
- Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema | Oculis
- Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema | Oculis
- Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress | Oculis
- Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase | Oculis
- Oculis to Present at Upcoming September Investor Conferences | Oculis
- Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update | Oculis
- OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery | Oculis
- View more press releases Close
Redes sociales sobre Oculis
- Oculis en Wikipedia, Google News y Yahoo Finance
- Oculis en LinkedIn, Twitter y YouTube
